CDK2 and neoplasm: In this study, the expression of the tumor-suppressive CDK inhibitor p27 was increased, and the expression of oncogenic CDK2 and CDK4; cyclins (A, D, and E); and pRb was decreased by galectin-1 knockdown and miR-22-3p overexpression in primary hormone receptor-positive breast cancer cells.